NASDAQ:VCYT - Veracyte Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $24.57 -0.18 (-0.73 %) (As of 05/24/2019 06:00 AM ET)Previous Close$24.75Today's Range$24.09 - $25.4852-Week Range$7.05 - $26.80Volume471,082 shsAverage Volume623,479 shsMarket Capitalization$1.02 billionP/E RatioN/ADividend YieldN/ABeta0.95 ProfileAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Veracyte, Inc. operates as a genomic diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas solutions for a complex landscape in thyroid nodule diagnosis to physicians; Percepta Bronchial Genomic Classifier solution for use in lung cancer diagnosis; and Envisia Genomic Classifier solution for the diagnosis of idiopathic pulmonary fibrosis. It sells its products through product specialists, account managers, and medical science specialists. Veracyte, Inc. has a strategic collaboration with Johnson & Johnson, LLC and Johnson & Johnson's Lung Cancer Initiative to advance diagnostics of a nasal swab test for early lung cancer detection; a research collaboration with Loxo Oncology for the development of therapies for patients with genetically defined cancers; and an agreement with Johnson & Johnson Services, Inc. for the development and commercialization of novel diagnostic tests to detect lung cancer. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California. Receive VCYT News and Ratings via Email Sign-up to receive the latest news and ratings for VCYT and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Medical laboratories Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:VCYT Previous Symbol CUSIPN/A CIK1384101 Webhttp://www.veracyte.com/ Phone650-243-6300Debt Debt-to-Equity Ratio0.15 Current Ratio6.32 Quick Ratio6.06Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$92.01 million Price / Sales11.12 Cash FlowN/A Price / Cash FlowN/A Book Value$2.01 per share Price / Book12.22Profitability EPS (Most Recent Fiscal Year)($0.62) Net Income$-23,000,000.00 Net Margins-15.51% Return on Equity-23.43% Return on Assets-14.69%Miscellaneous Employees270 Outstanding Shares41,643,000Market Cap$1.02 billion Next Earnings Date7/22/2019 (Estimated) OptionableOptionable Veracyte (NASDAQ:VCYT) Frequently Asked Questions What is Veracyte's stock symbol? Veracyte trades on the NASDAQ under the ticker symbol "VCYT." How were Veracyte's earnings last quarter? Veracyte Inc (NASDAQ:VCYT) announced its quarterly earnings data on Monday, February, 25th. The biotechnology company reported ($0.08) EPS for the quarter, beating the Zacks' consensus estimate of ($0.13) by $0.05. The biotechnology company earned $25.75 million during the quarter, compared to analyst estimates of $24.33 million. Veracyte had a negative net margin of 15.51% and a negative return on equity of 23.43%. View Veracyte's Earnings History. When is Veracyte's next earnings date? Veracyte is scheduled to release their next quarterly earnings announcement on Monday, July 22nd 2019. View Earnings Estimates for Veracyte. What guidance has Veracyte issued on next quarter's earnings? Veracyte issued an update on its FY 2019 earnings guidance on Monday, February, 25th. The company provided EPS guidance of for the period. The company issued revenue guidance of $113-117 million, compared to the consensus revenue estimate of $109.43 million. What price target have analysts set for VCYT? 4 analysts have issued 1-year target prices for Veracyte's stock. Their forecasts range from $11.00 to $17.00. On average, they anticipate Veracyte's share price to reach $13.4333 in the next twelve months. This suggests that the stock has a possible downside of 45.3%. View Analyst Price Targets for Veracyte. What is the consensus analysts' recommendation for Veracyte? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Veracyte in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Veracyte. Has Veracyte been receiving favorable news coverage? Media headlines about VCYT stock have been trending neutral recently, according to InfoTrie. InfoTrie identifies positive and negative news coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Veracyte earned a news impact score of 0.3 on InfoTrie's scale. They also assigned news articles about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the company's share price in the near term. Who are some of Veracyte's key competitors? Some companies that are related to Veracyte include Genomic Health (GHDX), InVitae (NVTA), Natera (NTRA), CareDx (CDNA), RadNet (RDNT), Celcuity (CELC), Enzo Biochem (ENZ), Fulgent Genetics (FLGT), Miragen Therapeutics (MGEN), PotNetwork (POTN), Psychemedics (PMD), Biocept (BIOC), Avant Diagnostics (AVDX), CBA Florida (CBAI) and First Choice Healthcare Solutions (FCHS). What other stocks do shareholders of Veracyte own? Based on aggregate information from My MarketBeat watchlists, some companies that other Veracyte investors own include Hawkins (HWKN), CA (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), Geron (GERN), Genocea Biosciences (GNCA), Netflix (NFLX), Honeywell International (HON) and Johnson & Johnson (JNJ). Who are Veracyte's key executives? Veracyte's management team includes the folowing people: Ms. Bonnie H. Anderson, Co-Founder, Chairman & CEO (Age 61)Mr. Christopher M. Hall, Pres & COO (Age 50)Mr. Keith S. Kennedy CFA, CPA, CFO & Sec. (Age 49)Dr. Giulia C. Kennedy Ph.D., Chief Scientific & Medical Officer (Age 60)Mr. Ashish Kheterpal, Chief Information Officer Who are Veracyte's major shareholders? Veracyte's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include ARK Investment Management LLC (8.31%), Gilder Gagnon Howe & Co. LLC (8.29%), BlackRock Inc. (6.66%), Cannell Capital LLC (3.04%), Goldman Sachs Group Inc. (2.22%) and TPG Group Holdings SBS Advisors Inc. (1.94%). Company insiders that own Veracyte stock include Bonnie H Anderson, Christopher M Hall, Evan/ Fa Jones, Giulia C Kennedy and Jesse I Treu. View Institutional Ownership Trends for Veracyte. Which institutional investors are selling Veracyte stock? VCYT stock was sold by a variety of institutional investors in the last quarter, including TPG Group Holdings SBS Advisors Inc., Assenagon Asset Management S.A., Cannell Capital LLC, BlackRock Inc., Pier Capital LLC, Marshall Wace LLP, Renaissance Technologies LLC and Quantum Capital Management. Company insiders that have sold Veracyte company stock in the last year include Bonnie H Anderson, Christopher M Hall, Giulia C Kennedy and Jesse I Treu. View Insider Buying and Selling for Veracyte. Which institutional investors are buying Veracyte stock? VCYT stock was acquired by a variety of institutional investors in the last quarter, including Gilder Gagnon Howe & Co. LLC, Nikko Asset Management Americas Inc., Sumitomo Mitsui Trust Holdings Inc., William Blair Investment Management LLC, Laurion Capital Management LP, AQR Capital Management LLC, Robeco Institutional Asset Management B.V. and Goldman Sachs Group Inc.. View Insider Buying and Selling for Veracyte. How do I buy shares of Veracyte? Shares of VCYT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Veracyte's stock price today? One share of VCYT stock can currently be purchased for approximately $24.57. How big of a company is Veracyte? Veracyte has a market capitalization of $1.02 billion and generates $92.01 million in revenue each year. The biotechnology company earns $-23,000,000.00 in net income (profit) each year or ($0.62) on an earnings per share basis. Veracyte employs 270 workers across the globe. What is Veracyte's official website? The official website for Veracyte is http://www.veracyte.com/. How can I contact Veracyte? Veracyte's mailing address is 6000 SHORELINE COURT SUITE 300, SOUTH SAN FRANCISCO CA, 94080. The biotechnology company can be reached via phone at 650-243-6300 or via email at [email protected] MarketBeat Community Rating for Veracyte (NASDAQ VCYT)Community Ranking: 3.1 out of 5 ( )Outperform Votes: 298 (Vote Outperform)Underperform Votes: 190 (Vote Underperform)Total Votes: 488MarketBeat's community ratings are surveys of what our community members think about Veracyte and other stocks. Vote "Outperform" if you believe VCYT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VCYT will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 5/24/2019 by MarketBeat.com StaffFeatured Article: Google Finance Portfolio Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.